Hugo Terrisse

Hugo Terrisse

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JGJ.‐P. Galanaud
J.‐P. Galanaud
MSM.‐A. Sevestre
M.‐A. Sevestre
GPG. Pernod
G. Pernod
CGC. Genty
C. Genty
SRS. Richelet
S. Richelet
JBJ.‐L. Bosson
J.‐L. Bosson

1 June 2017 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
JGJ.‐P. Galanaud
J.‐P. Galanaud
MSM.‐A. Sevestre
M.‐A. Sevestre
GPG. Pernod
G. Pernod
SKS. R. Kahn
S. R. Kahn
CGC. Genty
C. Genty
JBJ.‐L. Bosson
J.‐L. Bosson

21 October 2018 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
CLC. Landelle
C. Landelle
VBV. Nocquet Boyer
V. Nocquet Boyer
MAM. Abbas
M. Abbas
EGE. Genevois
E. Genevois
NAN. Abidi
N. Abidi
JPJ. Pugin
J. Pugin
Purpose We describe the impact of a multifaceted program for decreasing ventilator-associated pneumonia (VAP) after implementing nine preventive measures, including selective oropharyngeal decontamination (SOD). Methods We compared VAP rates during an 8-month pre-intervention period, a 12-month intervention period, and an 11-month post-intervention period in a cohort of patients who received mechanical ventilation (MV) for > 48 h. The primary objective was to assess the effect on first VAP occurrence, using a Cox cause-specific proportional hazards model. Secondary objectives included the impact on emergence of antimicrobial resistance, antibiotic consumption, duration of MV, and ICU mortality. Results Pre-intervention, intervention and post-intervention VAP rates were 24.0, 11.0 and 3.9 VAP episodes per 1000 ventilation-days, respectively. VAP rates decreased by 56% [hazard ratio (HR) 0.44, 95% CI 0.29–0.65; P < 0.001] in the intervention and by 85% (HR 0.15, 95% CI 0.08–0.27; P < 0.001) in the post-intervention periods. During the intervention period, VAP rates decreased by 42% (HR 0.58, 95% CI 0.38–0.87; P < 0.001) after implementation of eight preventive measures without SOD, and by 70% after adding SOD (HR 0.30, 95% CI 0.13–0.72; P < 0.001) compared to the pre-intervention period. The incidence density of intrinsically resistant bacteria (to colistin or tobramycin) did not increase. We documented a significant reduction of days of therapy per 1000 patient-days of broad-spectrum antibiotic used to treat lower respiratory tract infection (P < 0.028), median duration of MV (from 7.1 to 6.4 days; P < 0.003) and ICU mortality (from 16.2 to 13.5%; P < 0.049) for patients ventilated > 48 h between the pre- and post-intervention periods. Conclusions Our preventive program produced a sustained decrease in VAP incidence. SOD provides an additive value.

1 November 2018 in Thrombosis Research
Verified
Journal Article
Closed access
JGJean-Philippe Galanaud
Jean-Philippe Galanaud
SBSophie Blaise
Sophie Blaise
MSMarie-Antoinette Sevestre
Marie-Antoinette Sevestre
HTHugo Terrisse
Hugo Terrisse
GPGilles Pernod
Gilles Pernod
JBJean-Luc Bosson
Jean-Luc Bosson

21 June 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
CMClaire Masson
Claire Masson
GBGabriel Birgand
Gabriel Birgand
ECEnrique Castro-Sánchez
Enrique Castro-Sánchez
VEVanessa Maria Eichel
Vanessa Maria Eichel
ACAlexa Comte
Alexa Comte
CLCaroline Landelle
Caroline Landelle
Introduction Some surgical site infections (SSI) could be prevented by following adequate infection prevention and control (IPC) measures. Poor compliance with IPC measures often occurs due to knowledge gaps and insufficient education of healthcare professionals. The education and training of SSI preventive measures does not usually take place in the operating room (OR), due to safety, and organisational and logistic issues. The proposed study aims to compare virtual reality (VR) as a tool for medical students to learn the SSI prevention measures and adequate behaviours (eg, limit movements…) in the OR, to conventional teaching. Methods and analysis This protocol describes a randomised controlled multicentre trial comparing an educational intervention based on VR simulation to routine education. This multicentre study will be performed in three universities: Grenoble Alpes University (France), Imperial College London (UK) and University of Heidelberg (Germany). Third-year medical students of each university will be randomised in two groups. The students randomised in the intervention group will follow VR teaching. The students randomised in the control group will follow a conventional education programme. Primary outcome will be the difference between scores obtained at the IPC exam at the end of the year between the two groups. The written exam will be the same in the three countries. Secondary outcomes will be satisfaction and students’ progression for the VR group. The data will be analysed with intention-to-treat and per protocol. Ethics and dissemination This study has been approved by the Medical Education Ethics Committee of the London Imperial College (MEEC1920-172), by the Ethical Committee for the Research of Grenoble Alpes University (CER Grenoble Alpes-Avis-2019-099-24-2) and by the Ethics Committee of the Medical Faculty of Heidelberg University (S-765/2019). Results will be published in peer-reviewed medical journals, communicated to participants, general public and all relevant stakeholders.

15 November 2023 in European journal of pain
Verified
Journal Article
Open access
LDL. Druart
L. Druart
SLS. E. Graham Longsworth
S. E. Graham Longsworth
HTHugo Terrisse
Hugo Terrisse
CLC. Locher
C. Locher
CBC. Blease
C. Blease
Nicolas PinsaultNicolas Pinsault
Nicolas Pinsault
Background: Placebo use is widespread in clinical practice. However, they are most often administered deceptively rather than openly. It is often suggested that open‐label placebos (OLP) are less effective than deceptive placebos (DP). This study aimed to compare the use of DP and OLP treatments to reduce pain in healthy volunteers.Methods: We conducted a non‐inferiority, parallel, randomized, controlled trial, which also included a nested cross‐over no‐treatment condition. This study was conducted at a university clinic in France.Results: We included 60 subjects and the main result shows that the OLP was not inferior to the DP by a margin of 10 mm. The mean difference between both groups regarding intensity of pain was 0.7 mm with a 95% compatibility interval (95% CI) of ]−∞; 5.4], and 97.5% CI of ]−∞; 6.3]. Secondary outcomes require cautious interpretation of the effect of placebo versus no treatment due to a time–treatment interaction.Conclusion: The study indicates that OLP may perform just as well as DP and could provide support for the use of OLP as an ethical alternative to DP when they are to be used in a clinical setting. If only patients knew about the placebo nature of some treatments they are receiving, unnecessary lies could be avoided while maintaining similar placebo effects.Significance: This study is the first to show non‐inferiority of placebos administered honestly, also called OLP, compared to DP in reducing pain. This suggests that OLP could be as effective as their deceptive counterparts while having the ethical advantage of not being required to lie. If deception is not a necessary condition for efficacy, OLP should be preferred over DP.